| Literature DB >> 33677520 |
Joseph Keawe'aimoku Kaholokula1, Mele Look1,2, Tricia Mabellos1, Hyeong Jun Ahn3, So Yung Choi3, Ka'imi A Sinclair4, Thomas A Wills1,5, Todd B Seto1,6, Māpuana de Silva2.
Abstract
BACKGROUND: Native Hawaiians have higher hypertension (HTN) and cardiovascular disease (CVD) rates than non-Hispanic whites, calling for culturally responsive interventions to close this gap.Entities:
Keywords: Cardiovascular disease; Dance; Exercise; Hypertension; Intervention; Native Hawaiian
Mesh:
Year: 2021 PMID: 33677520 PMCID: PMC8489304 DOI: 10.1093/abm/kaaa127
Source DB: PubMed Journal: Ann Behav Med ISSN: 0883-6612
Fig. 1.CONSORT diagram of the randomized clinical trial.
Baseline characteristics of participants by study group
| Characteristic* | Intervention ( | Waitlist Control ( | |
|---|---|---|---|
| Age (years) | 58.1 ± 13.7 | 57.9 ± 12.6 | 0.88 |
| Female | 111 (84.7) | 109 (82.6) | 0.64 |
| Community site | 0.56 | ||
| Site 1 | 7 (5.3) | 10 (7.6) | |
| Site 2 | 44 (33.6) | 44 (33.3) | |
| Site 3 | 18 (13.7) | 16 (12.1) | |
| Site 4 | 12 (9.2) | 8 (6.1) | |
| Site 5 | 20 (15.3) | 14 (10.6) | |
| Site 6 | 30 (22.9) | 40 (30.3) | |
| Education level | 0.97 | ||
| Less than high school | 1 (0.8) | 1 (0.8) | |
| High School | 50 (38.5) | 48 (36.9) | |
| Some college | 51 (39.2) | 50 (38.5) | |
| College | 28 (21.5) | 31 (23.8) | |
| Marital status | 0.13 | ||
| Never married | 29 (22.1) | 27 (20.5) | |
| Currently married | 50 (38.2) | 66 (50.0) | |
| Disrupted marital status | 52 (39.7) | 39 (29.5) | |
| Other medical conditions | |||
| High cholesterol | 64 (48.9) | 69 (52.3) | 0.58 |
| Diabetes | 52 (39.7) | 66 (50.0) | 0.09 |
| Heart condition | 3 (2.3) | 6 (4.5) | 0.50 |
| Other medical conditions | 18 (13.7) | 25 (18.9) | 0.25 |
| No other medical condition | 36 (27.5) | 28 (21.2) | 0.24 |
| Prescribed HTN medication | 114 (87.0) | 113 (85.6) | 0.74 |
| No. of HTN medications | 1.31 ± 0.88 | 1.40 ± 0.87 | 0.37 |
| Smoking history | 0.10 | ||
| Never | 69 (52.7) | 79 (59.8) | |
| Former | 44 (33.6) | 45 (34.1) | |
| Current | 18 (13.7) | 8 (6.1) | |
| Weight, kg | 93.5 ± 19.0 | 99.7 ± 28.1 | 0.04 |
| Height, cm | 163.6 ± 7.8 | 164.4 ± 9.3 | 0.48 |
| Body-mass-index, kg/m2 | 34.9 ± 6.4 | 36.7 ± 9.3 | 0.07 |
| Systolic blood pressure, mmHg | 144.1 ± 16.9 | 145.1 ± 13.9 | 0.60 |
| Diastolic blood pressure, mmHg | 85.2 ± 12.6 | 84.5 ± 10.4 | 0.64 |
| High-density lipoproteins, mg/dL‡ | 48.8 ± 14.6 | 46.5 ± 15.1 | 0.24 |
| Total cholesterol, mg/dL‡ | 174.0 ± 31.4 | 177.3 ± 42.3 | 0.48 |
* Data are shown as mean ± standard deviation or number (percentages); numbers for some variables may not equate to total sample size because of missing data.
† Group difference p values based on two-sample independent t-tests and Chi-squared or Fisher’s exact tests, as appropriate.
‡ Sample size reduced to 247 for high-density lipoproteins (123 intervention; 124 control) and 250 for total cholesterol (126 intervention; 124 control) due to unreliable data.
Comparison of blood pressure (BP) outcomes from baseline to 3- and 6-month follow-up between intervention and control group
| Outcome | Baseline to 3 months | Baseline to 6 months | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| 3-month | Within-group difference | Between-group difference (95% CI) |
|
| Baseline | 6-month | Within-group difference | Between-group difference (95% CI) |
| ||
|
| ||||||||||||
| Intention-to-treat | −3.6 (−6.0, −1.2) | 0.04 | −3.9 (−6.4, −1.4) | 0.04 | ||||||||
| Intervention | 131 | 144.1 ±16.9 | 129.4 ± 16.4 | −14.7 ± 19.0 | 131 | 144.1 ± 16.9 | 128.9 ± 16.3 | −15.3 ± 18.8 | ||||
| Control | 132 | 145.1 ± 13.9 | 133.6 ± 19.1 | −11.5 ± 19.1 | 132 | 145.1 ± 13.9 | 133.3 ± 18.7 | −11.8 ± 19.5 | ||||
| Complete cases | −2.6 (−5.4, 0.1) | 0.17 | −5.7 (−8.5, −2.8) | 0.01 | ||||||||
| Intervention | 126 | 144.3 ± 17.1 | 129.0 ± 16.5 | −15.3 ± 19.1 | 105 | 145.2 ± 17.9 | 128.2 ± 15.6 | −16.9 ± 18.5 | ||||
| Control | 116 | 144.2 ± 13.3 | 131.2 ± 18.1 | −13.1 ± 19.8 | 112 | 144.2 ± 12.8 | 132.6 ± 17.0 | −11.5 ± 18.1 | ||||
|
| ||||||||||||
| Intention-to-treat | −3.5 (−4.9, −2.2) | 0.04 | −4.0 (−5.7, −2.2) | 0.02 | ||||||||
| Intervention | 131 | 85.2 ± 12.6 | 78.5 ±13.0 | −6.7 ± 12.6 | 131 | 85.2 ± 12.6 | 78.8 ± 10.9 | −6.4 ±11.8 | ||||
| Control | 132 | 84.6 ± 10.4 | 81.2 ± 12.6 | −3.3 ± 10.9 | 132 | 84.6 ± 10.4 | 81.9 ± 11.3 | −2.6 ± 11.3 | ||||
| Complete cases | −3.3 (−4.8, −1.8) | 0.08 | −4.6 (−6.6, −2.5) | 0.01 | ||||||||
| Intervention | 126 | 85.1 ± 12.7 | 78.2 ± 13.1 | −7.0. ± 12.8 | 105 | 85.5 ± 12.5 | 78.1 ± 10.1 | −7.4 ± 11.7 | ||||
| Control | 116 | 84.4 ± 10.7 | 80.6 ± 13.0 | −3.8 ± 11.6 | 112 | 84.8 ± 10.6 | 81.8 ± 10.8 | −2.9 ± 11.9 |
*p values are based on between-group comparisons using a multivariable linear regression model with the BP change (follow-up value minus baseline value) as the dependent variable, adjusting for the baseline BP value, weight (kg), and community site. Intervention effect estimates are the difference in means and 95% confidence intervals (CI), net same adjustments.
Comparison of three hypertension stages at 6-month follow-up between intervention and control group
| Hypertension stage | Intervention | Control | Relative risk (95% CI) |
|
|---|---|---|---|---|
| Intention-to-treat | ||||
| <140/90 mm Hg | 94 (71.8%) | 81 (61.4%) | 1.1 (0.9, 1.3) | 0.13 |
| <135/85 mm Hg | 74 (56.5%) | 55 (41.5%) | 1.3 (1.1, 1.5) | 0.02 |
| <130/80 mm Hg | 56 (42.7%) | 28 (21.2%) | 1.8 (1.4, 2.2) | <0.001 |
| Complete cases | ||||
| <140/90 mm Hg | 78 (74.3%) | 70 (62.5%) | 1.2 (1.0, 1.3) | 0.04 |
| <135/85 mm Hg | 61 (58.1%) | 47 (42.0%) | 1.4 (1.1, 1.6) | <0.001 |
| <130/80 mm Hg | 47 (44.8%) | 23 (20.5%) | 2.0 (1.5, 2.5) | <0.0001 |
Data are shown as number (%) within-group and relative risk (95% confidence intervals) between-group.
* p values are based on between-group comparisons using a multivariable logistic regression model, adjusting for baseline systolic BP, weight (kg), and community site. Intervention effect estimates are relative risk and 95% confidence intervals (CI), net same adjustments.
Comparison of 10-year cardiovascular disease risk based on the Framingham Risk Score—Cardiovascular Disease (FRS-CVD) calculator from baseline to 6-month follow-up between intervention and control group.
| FRS-CVD |
| Baseline | 6-month | Within-group change | Intervention effect (95% CI) |
|
|---|---|---|---|---|---|---|
| Intention-to-treat | −2.8 (−4.1, −1.4) | 0.02 | ||||
| Intervention | 120 | 19.6% ± 15.8 | 14.5% ± 10.8 | −5.2% ± 10.9 | ||
| Control | 122 | 19.9% ± 14.4 | 17.4% ± 15.3 | −2.5% ± 9.5 | ||
| Complete cases | −4.3 (−6.0, −2.5) | <0.01 | ||||
| Intervention | 87 | 21.0% ± 16.3 | 14.3% ± 9.6 | −6.7% ± 10.8 | ||
| Control | 97 | 19.2% ± 13.7 | 16.6% ± 14.6 | −2.6% ± 9.5 |
*p values are based on between-group comparisons using a multivariable linear model with the prevent risk change (follow-up value minus baseline value) as the dependent variable, adjusting for baseline weight (kg), and community site. Intervention effect estimates are the difference in means and 95% confidence intervals (CI), net same adjustments.
†Sample size reduced due to missing cholesterol data at baseline.